Skip to main content
. 2018 Mar 23;9(22):16028–16042. doi: 10.18632/oncotarget.24678

Figure 3. Suppression of miR-182-5p mediated binding of AGO2 to SESN2 mRNA following treatment with ATO.

Figure 3

(A) RNP-IP was used to evaluate the binding ability of AGO2 to SENS2 mRNA and TP53INP1 mRNA before and after ATO treatment (see text) (n=3). (B) The influence of manipulating miR-182-5p expression on AGO2 binding to SESN2 mRNA and TP53INP1 mRNA. (C) Suppression of miR-183/96/182 gene cluster expression by ATO. (D) ATO-mediated suppression of miR-182-5p expression was rescued by TGF-β. (E) A putative model shows ATO inhibiting the binding of AGO2 to mRNA via suppression of miR-182-5p expression. *: p<0.05.